

PRESS RELEASE For release: 3 April 2023 14.30 CET/8.30 EST

More than 400,000,000 European and International endocrine patients urge Brussels to take action on REACH revision.

Brussels, Belgium 3 April 2023—A broad coalition of endocrine patient representatives and experience experts for over 400,000,000 European and international patients have today called on EU legislators to publish the revised REACH proposal without any further delay and no later than June 2023.

Citing the urgent and immediate need to minimise exposure to Endocrine Disrupting Chemicals (EDCs) in the interest of public health, the patients insist that flaws in the REACH regulation must be addressed without delay. EDCs are not a compromise area, and extending the current legislation is required to fulfil the mentioned objectives.

The [petition](#) was launched by the [Patient Advocacy Group of European Society of Endocrinology](#) (EPAG) and signed until now by 8 international patient associations representing about 300 national patient organisations across the world and more than 40 national endocrine patient (informing) organisations. Together they represent the European and international endocrine patient community. The petition has been submitted to the European Commission.

The patients are extremely concerned that the current REACH regulation does not effectively address the numerous health impacts stemming from EDC exposure. The necessary steps to reduce exposure to hazardous EDCs and establish lasting protection for human health can only come in a revision of REACH itself.

EDCs are not an area for compromise. An immediate and rigorous revision and extension to the current legislation is needed to effectively address the many current adverse health impacts. Any further delay to the phase out of ESEs is unacceptable.

EDCs, which include bisphenols, phthalates, and PFAS, among other chemicals in commerce, are pervasive and linked to serious adverse effects on endocrine systems leading to diseases such as infertility, diabetes, cancer, and altered neurological development.

Health impacts, impacts on the quality of life and impacts of social exclusion of patients from EDC exposures are widespread and cause suffering for patients and their relatives throughout the European Union. Moreover, individuals such as pregnant women and children are uniquely susceptible to the effects of endocrine disruption, meaning that action now can prevent harm to current and future generations.

In addition to the huge impact on human and ecological health, EDCs are also linked to massive economic costs borne by EU citizens: [conservative estimates](#) have linked EDC exposures to **some €157bn**, in additional health care costs and lost earnings.

**** ENDS ****

Contacts:

Johan de Graaf
j.degraaf@hypofyse.nl

Jo Grey
jo.grey@amend.org.uk

Peter Lakwijk
Peter.lakwijk@thyroid-fed.org

Tel.: 0046 761 702 309

Organisation

Addison Foreningen i Danmark
Association for Multiple Endocrine Neoplasia Disorders (AMEND)
Turner Syndrome Support UK
Clinic NeoLab
British Thyroid Foundation
Medicine
Thyroid UK
Thyroid Federation International
Hadassah Medical Center
World Alliance of Pituitary Organizations
Thyroid UK
Universidade Estadual do Centro-Oeste
Univerisdad Peruana Cayetano Heredia
Vivre sans Thyroide
International Prader-Willi Syndrome Organisation
C.A.P.E.
European MEN Alliance e.V.
AdrenalNET/BijnierNET
Association for rare diseases Croatia
AMEIRODV-Association for Endocrine Patients Irpina Voluntary
Organization
Unicentro
Associazione Iperplasia surrenale congenita - CAH Italia
Clinic Solomed; Batumi Endocrinology Center
University of Campania
Erasmus mc
Associazione Medici Endocrinologi
ThyroidUK
Europa Uomo Schweiz
USMF "Nicolae Testemitanu"
AECAT
Hypopara Norway
National hospital of the Faroe Islands
Dutch Pituitary Foundation
Nvacp
Addison's Disease Self-Help Group
Dutch Pituitary Foundation/Endo-ERN
Clínica los Yoses
Living with CAH Support Work
MVZ Endokrinologikum
University Hospital of Zurich
Thyroid Awareness and Support Initiative
AIPAd
Bijniervereniging NVACP
SOD ITALIA ONLUS
AMATIM Associazione Malati Tiroidei delle Marche
THE HORMONE CLINIC
Finnish Apeced and Addison Association

Country

Denmark
United Kingdom
United Kingdom
Georgia
United Kingdom
Romania
United Kingdom
Spain
Israel
Netherlands
United Kingdom
Brazil
Peru
France
United Kingdom
Italy
Germany
Netherlands
Croatia
Italy

Brazil
Italy
Georgia
Italy
Netherlands
Italy
United Kingdom
Switzerland
Moldova
Spain
Norway
Faroe Islands
Netherlands
Belgium
United Kingdom
Netherlands
Costa Rica
United Kingdom
Germany
Switzerland
Nigeria
Italy
Netherlands
Italy
Italy
India
Finland

Northeast Endocrinology Associates

United States